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ABSTRACT Theactionsofmanybacterialtoxinsdependontheirabilitytobindtooneormorecell-surfacereceptors.Anthrax
toxinactsbyasequenceofeventsthatbeginswhentheprotective-antigen(PA)moietyofthetoxinbindstoeitheroneof
twocell-surfaceproteins,ANTXR1andANTXR2,andisproteolyticallyactivated.TheactivatedPAself-associatestoformoligo-
mericporeprecursors,which,inturn,bindtheenzymaticmoietiesofthetoxinandtransportthemtothecytosol.Weintro-
ducedadoublemutationintodomain4ofPAtoablateitsnativereceptor-bindingfunctionandfusedepidermalgrowthfactor
(EGF)totheCterminusofthemutatedprotein.Theresultingfusionproteintransportedenzymaticeffectorproteinsintoacell
linethatexpressedtheEGFreceptor(A431cells),butnotintoalinelackingthisreceptor(CHO-K1cells).Additionofexcessfree
EGFblockedtransportofeffectorproteinsintoA431cellsviathefusionprotein,butnotvianativePA.Wealsoshowedthatfus-
ingthediphtheriatoxinreceptor-bindingdomaintotheCterminusofthemutatedPAchanneledeffector-proteintransport
throughthediphtheriatoxinreceptor.PAfusionproteinswithalteredreceptorspeciﬁcitymaybeusefulinbiologicalresearch
and could have practical applications, including ablation or perturbation of selected populations of cells in vivo.
IMPORTANCE Bacterialtoxinsthatactwithinmammaliancellshavereceptor-dependentmechanismstotransporttheirenzy-
maticcomponentstothecytoplasmiccompartment.Byinactivatingorotherwisemodifyingtheirrespectiveintracellulartargets,
theseintracellulareffectorsdisruptmetabolicpathwaysandinsomecasescausedeathofthecell.Ourresultsshowthatthere-
ceptorspeciﬁcityofthetransportproteinofanthraxtoxinmaybereadilychanged,raisingthepossibilitythatreceptor-
redirectedformsofprotectiveantigen(PA)andPAhomologsmaybeusefulforresearchandmedicalapplicationsrequiring
modiﬁcationorablationofdesignatedpopulationsofcells.
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T
argeting of toxic proteins to speciﬁc classes of mammalian
cellshasbeenstudiedextensivelyinrecentyears,oftenwiththe
goal of developing new treatments for malignancies (1). One ap-
proach to targeting involves replacing the receptor-binding do-
main of a toxin with a heterologous protein, such as a growth
factor or antibody that binds to a speciﬁc cell-surface receptor.
Another approach is to link a heterologous protein to an altered
form of the toxin in which the native receptor-binding function
has been disrupted. We used the latter approach to redirect the
receptorspeciﬁcityofthetransportmoietyofanthraxtoxin(ATx)
to either one of two heterologous receptors.
Anthraxtoxinisanensembleofthreelargeproteins:protective
antigen (PA) (83 kDa), lethal factor (LF) (90 kDa), and edema
factor (EF) (89 kDa) (2). LF and EF are enzymes (“effector pro-
teins”) that modify substrates residing within the cytosolic com-
partmentofmammaliancells.LFisametalloproteasethatcleaves
most members of the mitogen-activated protein (MAP) kinase
kinase family, and EF is a calmodulin- and Ca2-dependent ad-
enylyl cyclase, which elevates the level of cyclic AMP (cAMP)
within the cell (3–5). PA is a receptor-binding transporter, which
is capable of forming pores in the endosomal membrane (2, 6).
TheseporesmediatethetranslocationofEF,LF,orvariousfusion
proteins containing the N-terminal PA-binding domain of EF or
LF across the endosomal membrane to the cytosol (7).
ATx action at the cellular level is initiated when PA binds to
either one of two receptors, ANTXR1 and ANTXR2 (8, 9), and is
activated by a furin class protease (10). The cleavage yields a 20-
kDa fragment, PA20, which is released into the surrounding me-
dium, and a 63-kDa fragment, PA63, which remains bound to the
receptor. Receptor-bound PA63 spontaneously self-associates to
form ring-shaped heptameric (11) and octameric (12) oligomers
(prepores),whicharecapableofbindingLFand/orEFwithnano-
molarafﬁnity(13,14).Theresultingheterooligomericcomplexes
are endocytosed and delivered to the endosomal compartment,
where acidic pH induces the prepores to undergo a conforma-
tional rearrangement that enables them to form pores in the en-
dosomalmembrane(2).Theseporesserveasproteintranslocases,
which unfold bound LF and EF molecules and transport them
across the endosomal membrane, where they refold and modify
their respective intracellular targets.
Both PA receptors—ANTXR1 (also called TEM8) and
ANTXR2 (also called CMG2)—are type 1 membrane proteins
containing a von Willebrand/integrin A (VWA) MIDAS domain
(2). Within PA, both domain 4, the so-called receptor-binding
domain, and domain 2, the pore-forming domain, participate in
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and ANTXR2 have different afﬁnities for PA (16, 17), but both of
these receptors bind PA in a manner that allows it to be proteo-
lytically activated and to oligomerize and both receptors mediate
trafﬁcking of prepore-effector complexes to the endosomal com-
partment and translocation across the endosomal membrane.
Inthisstudy,weablatedthereceptor-bindingactivityofPAby
mutatingtworesidueswithindomain4andthenfusedeachoftwo
heterologous receptor-binding proteins, human epidermal
growth factor (EGF) or the receptor-binding domain of diphthe-
riatoxin(DTR),totheCterminusofthemutatedprotein(Fig.1).
Bothoftheresultingfusionproteinsmediatedtheentryofeffector
enzymes, and entry was dependent in each case on the cellular
receptor recognized by the receptor-binding polypeptide ap-
pended to PA.
RESULTS
We introduced two mutations, N682A and D683A, into PA to
ablateitsnativereceptor-bindingfunction(18),andexpressedthe
mutated protein (mPA) in Escherichia coli BL21(DE3). The puri-
ﬁed product failed to promote entry of LFN-DTA into either
CHO-K1 cells or A431 cells at the highest concentration tested
(10nM),asmeasuredbytheinhibitionofproteinsynthesisinthe
presence of LFN-DTA. LFN-DTA is a fusion between LFN, the
N-terminal PA63-binding domain of LF, and DTA, the catalytic
domain of diphtheria toxin. The DTA moiety catalyzes the ADP-
ribosylation of eukaryotic elongation factor 2 (eEF-2) within the
cytosol,blockingproteinsynthesisandcausingcelldeath(19,20).
The proteolytically activated form of mPA, mPA63, was able to
formSDS-resistant,high-molecular-weightaggregates,character-
isticofpores,althoughthepHdependenceofporeformationwas
somewhat altered (Fig. 2A).
Having demonstrated that the N682A/D683A double muta-
tion blocked the receptor-binding function of PA, we fused hu-
man EGF to the C terminus of the mutated protein (mPA-EGF).
Puriﬁed monomeric mPA-EGF was stable and ran slightly slower
than native PA on SDS-polyacrylamide gels, consistent with its
higher molecular weight (Fig. 2B). Western blots showed that the
productreactedwithbothanti-PAandanti-EGFantibodies.Also,
it was shown that the mPA63-EGF fragment derived by trypsin
treatment formed high-molecular-weight aggregates on SDS-
polyacrylamide gels similar to those seen with mPA63 (Fig. 2A).
A431 cells, which express high levels of the EGF receptor
(EGFR) (21, 22), were killed by LFN-DTA (50% effective concen-
tration [EC50] of ~10 pM) in the presence of mPA-EGF, whereas
CHO-K1 cells, which do not express the EGF receptor, were not
killed (Fig. 3A). Wild-type PA also mediated the inhibition of
protein synthesis in A431 cells, but a high concentration of LFN-
DTA (EC50 of ~100 pM) was needed, suggesting that these cells
express a lower level of ANTXR1, ANTXR2, or both. A
translocation-deﬁcientPAmutant,PAF427H(23),didnotmediate
killing of either A431 or CHO-K1 cells (data not shown).
IftheentryofLFN-DTAintoA431cellsmediatedbymPA-EGF
were dependent on binding to the EGF receptor, then addition of
freeEGFshouldcompeteforbindingandblocktoxicity.Asshown
in Fig. 3B, a 50-fold excess of EGF completely protected the cells
fromthecytotoxiceffectsofLFN-DTA,whereasthesameconcen-
tration of the PA-binding VWA domain of ANTXR2 had no ef-
fect. In contrast, cytotoxicity mediated by wild-type PA on A431
FIG 1 Composite representation of the heptameric prepore formed by PA63
(ProteinDataBank[PDB]accessionno.1TZO)withEGF(PDBaccessionno.
1JL9) linked to the C terminus. An axial view of the heptameric prepore is
shown,withdomains1,2,3,and4inasinglesubunitofPA63coloredmagenta,
green, gold, and purple, respectively. EGF is in red. Broken lines represent an
8-amino-acidlinker(SPGHKTQP)connectingtheNterminusofEGFtotheC
terminus of PA63.
FIG 2 Characterization of puriﬁed mPA-EGF. (A) Conversion of PA63 oli-
gomers from the SDS-dissociable prepore state (black arrow) to the SDS-
resistant pore state (gray arrow) at different pH values. Samples (5 g) of
native (83 kDa) and proteolytically activated ([63]7) forms of WT PA, mPA,
and mPA-EGF were separated by SDS-PAGE and visualized by Coomassie
bluestaining.(B)Westernblotanalysiswithanti-PAandanti-EGFantibodies
demonstrating the presence of both the PA and EGF epitopes in the puriﬁed
fusion protein.
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to a signiﬁcant degree by EGF (Fig. 3C).
WetestedtheabilityofmPA-EGFtotranslocateLFandEF,the
native effector moieties of anthrax toxin, into A431 cells. LF inac-
tivatesmitogen-activatedproteinkinasekinases(MEKs)bycleav-
ing near their N termini (3, 5), and we measured LF entry by
Western blotting of cell lysates with an anti-MEK1 antibody after
incubating cells with LF plus PA or a PA variant. MEK1 was
cleavedcompletelywithLFincombinationwithPAormPA-EGF,
but not in combination with the translocation-deﬁcient mutant
PAF427H (Fig. 4A). We measured entry of EF using an enzyme-
linked competition assay to determine the intracellular level of
cyclic AMP (cAMP) and observed a 400-fold elevation of cAMP
when mPA-EGF was used as the transporter (Fig. 4B). This level
was~100timeshigherthanthatobservedwhenwild-typePA(WT
PA) was used as the transporter. The level of cAMP when mPA or
PAF427H was used as the transporter was identical to the back-
ground level. The strong elevation observed with mPA-EGF was
likely due in part to the high level of EGF receptor (EGFR) on the
A431 cells. The fact that cleavage of MEK1 was complete when LF
was delivered via WT PA or mPA-EGF, whereas the amount of
cAMP generated by EF delivered by mPA-EGF was vastly greater
than when EF entered via WT PA may reﬂect differences in reac-
tionkineticsandthelevelsofsubstratesofthetwoeffectorswithin
cells.
Wepreparedasecondfusionprotein,inwhichthe150-residue
receptor-binding domain of diphtheria toxin (DTR) was fused to
the C terminus of mPA. The puriﬁed mPA-DTR fusion reacted
FIG 3 Cytotoxicity assays demonstrate receptor-speciﬁc cell targeting of
mPA-EGF.(A)A431orCHO-K1cells(3.5104)wereincubatedwith10nM
PA or PA variant plus LFN-DTA at the concentrations indicated. After a 4-h
incubation(A431cells)orovernightincubation(CHO-K1cells),themedium
was replaced with medium containing 1 Ci of [3H]leucine/ml. Following a
1-h incubation, incorporated [3H]leucine was determined by scintillation
counting.(BandC)AssayswereperformedasdescribedaboveforpanelA,but
soluble EGF (500 nM) or the PA-binding VWA domain of ANTRX2
(ANTRX2;100nM)waspresentduringa4-hincubationwithA431cells.Each
point on the curves represents the average of three experiments.
FIG 4 mPA-EGF transports LF and EF into EGFR-bearing cells. (A) A431
cells (1  106) were treated with 100 nM LF plus 10 nM PA or PA variant for
3 h. Cell lysates were prepared, fractionated by SDS-PAGE, and transferred to
a PVDF membrane, and MEK1 cleavage was evaluated by Western blotting
with anti-MEK1 antibody. For a control, GAPDH was monitored with anti-
GAPDHantibodies.(B)A431cells(3.5104)wereexposedto50nMEFplus
10 nM PA or PA variant for 1 h. A competition enzyme-linked immunoassay
was performed to detect the intracellular concentration of cAMP, based on a
standard curve, following the protocol of the manufacturer (Cell Signaling
Technology).Thecolumnlabeled“Control”correspondstoA431cellstreated
with EF in the absence of PA. Each bar represents the average of experiments
performed in quadruplicate.
Receptor Speciﬁcity of Anthrax Toxin
May/June 2012 Volume 3 Issue 3 e00088-12
® mbio.asm.org 3with both anti-PA and anti-diphtheria toxin antibodies (see
Fig. S1A in the supplemental material) and retained the ability to
oligomerize and form pores after activation. The activated form
bound and translocated LFN-DTA in a planar bilayer system
(Fig. S1B). The mPA-DTR variant delivered LFN-DTA into
CHO-K1 cells, inhibiting protein synthesis, and soluble DTR
competitively blocked this inhibition (Fig. S1C).
DISCUSSION
Viewing PA in broad perspective as a vehicle for delivering pro-
teins to the cytosolic compartment of mammalian cells, one is
struckbyitsadaptability.TheabilityofPAtotransporttwostruc-
turally disparate enzymes, LF and EF, into cells suggested that it
mightbecapableofdeliveringheterologousproteins,andindeed,
delivery of several such proteins and peptides has been demon-
strated following their fusion to the PA63-binding domain of LF
(24–30). A second mode of adaptability is illustrated by studies in
which the furin activation site within PA was replaced with sites
speciﬁcforotherproteasesforthepurposeoftumortargeting(31,
32).Thecurrentstudydemonstratesathirdmodeofadaptability,
namely, that the protein transport activity of PA can be readily
channeled through heterologous cell-surface receptors.
mPA-EGF was able to transport LF, EF, and the LFN-DTA fu-
sionproteintothecytosol,suggestingthattheessentialoligomer-
izationandtransportfunctionsofPAwerenotperturbedbychan-
neling entry through surrogate receptors. One of the surrogate
binding domains examined, DTR, performs an analogous func-
tion in an unrelated toxin (33), whereas the other, EGF, has no
relationship to bacterial toxin action, as far as we know. Both of
theseproteinsbindtoreceptorsthat,likeANTXR1andANTXR2,
internalize their ligands and trafﬁc them to an acidic intracellular
compartment. It is likely that entry into an acidic compartment is
essentialforproperfunctioningofPAfusionproteins,because(i)
acidic intravesicular pH plays a crucial role in promoting conver-
sion of the PA prepore to the pore (6, 7) and (ii) the pH gradient
across the endosomal membrane is essential for protein translo-
cation (34).
The decision to fuse surrogate receptor ligands to the C termi-
nusofmPA,insteadofreplacingdomain4withtheseligands,was
based on results indicating that domain 4 stabilizes the prepore
(35). Domain 4 must pivot away from domain 2 to allow the
pore-forming loop to be relocated to the base of the structure, so
that the transmembrane -barrel stem of the pore can be formed
(35).Weakcontactofdomain4withdomain2withinPA63inhib-
itsthispivotingandpreventsprematureconversionoftheprepore
tothepore.Thus,retainingdomain4inmutatedformallowedus
tochangereceptorspeciﬁcitywhileminimizingthelikelihoodthat
the process of prepore-to-pore conversion would be perturbed.
The pH threshold at which the prepore transitions to the pore
can be affected by various factors, including receptor binding.
When the native receptors bind to PA, they form contacts with
domain 2 as well as domain 4 and thereby stabilize the prepore,
causing the pH threshold to be shifted towards a more acidic
value. This effect should be obviated by ablating the receptor-
binding activity of domain 4. In fact, we found that the mPA
prepore,unlikethenativeprepore,underwentsomeconversionto
pores at pH 8.5 (Fig. 2A) even in the absence of native receptor. It
maybepossibletoidentifyalternativemutationsindomain4that
eliminate native receptor binding activity while causing less per-
turbationofpreporestability.Ashiftinthedependenceofchime-
ric, receptor-redirected forms of PA on pH may cause the
prepore-to-pore conversion to occur at an earlier stage of the en-
docytic pathway and possibly even allow some conversion to take
place at the cell surface. Regardless, the potency of the constructs
evaluated in the current study suggests that any shift in the pH
threshold did not greatly diminish the overall ability of PA to
deliver effector proteins to the cytosol.
Redirecting PA-dependent protein transport through heterol-
ogous cellular receptors may have applications both in experi-
mental science and medicine. Leppla and coworkers have ex-
plored targeting of PA to tumor cells by changing the proteolytic
activation site. Modiﬁed forms of PA were used to deliver FP59, a
cytotoxicfusionproteinsimilartoLFN-DTA,tothecytosolofcells
enriched in urokinase or matrix metalloprotease (31, 32). Like
these proteases, EGFR is enriched on several tumors (36), and
thus, mPA-EGF could potentially serve as an alternative means of
targeting. Other ligands whose receptors are enriched on target
cells would also be candidates for fusion to mPA.
One can envision use of receptor-targeted PA variants to de-
liver a wide variety of proteins (nontoxic and toxic proteins) to
chosenclassesofcells.However,fusiontoLFNdoesnotrenderall
proteins transportable by PA. Like DTA, the catalytic domains of
Shiga toxin and pseudomonas exotoxin A, and some nontoxic
proteins, including beta-lactamase, dihydrofolate reductase
(DHFR), and ciliary neurotrophic factor, were found to be trans-
ported by PA when fused to LFN (24, 25, 30, 37), but LFN fusions
of other proteins, including tetanus toxin light chain, botulinum
toxinElightchain,acidicﬁbroblastgrowthfactor,basicﬁbroblast
growth factor, and HIV Tat protein, were not transported. Intro-
ductionofanartiﬁcialdisulﬁdeintotheDTAmoietyofLFN-DTA
blocked translocation, as did liganding of LFN-DTA and LFN-
DHFR by adenine and methotrexate, respectively (30). These
ﬁndingsareconsistentwitharequirementthatproteinsunfoldin
order to be translocated through the PA pore, and the propensity
tounfoldunderacidicconditionsmaythereforebeamajordeter-
minant of the ability of a protein to be translocated.
In conclusion, despite limitations, the PA-based transport of
proteins offers a wide range of adaptability and warrants further
study for a variety of applications.
MATERIALS AND METHODS
Reagents and chemicals. Oligonucleotides were from Integrated DNA
Technologies(Coralville,IA).Sigma-Aldrich(St.Louis,MO)suppliedall
chemicalsunlessnotedotherwise.AsynthetichumanEGFgene,adjusted
for E. coli expression, was a generous gift from E. Joop van Zoelen (De-
partment of Cell Biology and Applied Biology, Radboud University Ni-
jmegen, Nijmegen, The Netherlands). Soluble EGF was from ProSpec-
Tany Technogene Ltd. (East Brunswick, NJ).
GenerationofPAexpressionplasmids.ThetwoPAchimerasusedin
this work, PAN682AD683A-EGF (mPA-EGF) and PAN682AD683A-DTR
(mPA-DTR), were created by overlap extension PCR using a previously
generated PAN682AD683A (mPA) gene coding sequence. In both cases, the
ﬁrstPCRstepconsistedoftworeactions.Theﬁrstreactionusedaforward
primer,PAFor(Forstandsforforward)(GATTTAGTAATTCGAATTCA
AGTACGG),pluseitherPARevEGF(Revstandsforreverse)(CATTCAG
AGTCGCTGTTTGGTTGCGTTTTATG) or PARevDTR (GTTTTATGC
CCCGGAGATCCTATCTCATAGCC) as the reverse primer. The PAR
evEGFandPARevDTRprimerscontainedtheEGFandDTRoverlapping
regions, respectively. In the second reaction, forward and reverse primers
were used to amplify the EGF sequence (EGFFor [CATAAAACGCAACC
AAACAGCGACTATGAATG] and EGFRev [GGTGGTGCTCGAGTCA
ACGGAGCTCCCACCATTTC]) and DTR sequence (DTRFor [GGCTA
Mechaly et al.
4
® mbio.asm.org May/June 2012 Volume 3 Issue 3 e00088-12TGAGATAGGATCTCCGGGGCATAAAAC] and DTRRev [GTGGTGG
TGGTGGTGCTCGAGTCAGCTTTTGATTTC]) sequences. The
PCR-generatedDNAfragmentswerethensubjectedtoasecondPCRstep
using forward primer PAFor in combination with either the EGFRev or
DTRRev primer, for PA-EGF and PA-DTR, to stitch and amplify the two
fragments together. In both cases, the full-length PCR products encoded
EcoRI and XhoI restriction sites (indicated in the primer sequences in
bold)intheforwardandreverseprimers,respectively.ThePCRproducts
were restriction digested and cloned into the pet22b expression vector by
standard protocols. Each clone also coded for an 8-residue linker (SPGH
KTQP) between PA and either EGF or DTR, which is part of the natural
linker between the transmembrane and receptor-binding domains of
diphtheria toxin.
Protein expression and puriﬁcation. Recombinant wild-type PA
(WT PA), PAF427H, mPA, mPA-EGF, and mPA-DTR were overexpressed
in the periplasm of the E. coli BL21(DE3) strain (Invitrogen, Carlsbad,
CA). The resulting bacterial pellets were lysed and puriﬁed as described
previously (6). Oligomeric prepores of WT PA and the various PA vari-
antswereproducedbylimitedtrypsindigestionataﬁnaltrypsin/PAratio
of 1:1,000 (wt/wt) for 30 min at room temperature (RT). The nicked
proteins were subjected to anion-exchange chromatography, resulting in
theseparationofPA63andPA20fragments.PA63spontaneouslyoligomer-
ized to form prepore.
Puriﬁed mPA-EGF and mPA-DTR fusions were characterized by
Western blot analysis. PA83 variants along with WT PA were subjected to
SDS-PAGE and transferred to a polyvinylidene diﬂuoride (PVDF) mem-
brane (Invitrogen, Carlsbad, CA). The membranes were blocked with
Tris-bufferedsaline(pH7.4)containing2%bovineserumalbumin(BSA)
and hybridized with either mouse anti-PA antibodies (diluted 1:4,000)
(catalog no. MAB8082; Millipore, Billerica, MA), rabbit anti-EGF anti-
bodies (1:50,000) (catalog no. Ab9695; Abcam, Cambridge, MA), or rab-
bitanti-DTantibodies(1:20,000)(catalogno.Ab53828;Abcam).Primary
antibodies were detected with either goat anti-rabbit IgG (1:20,000) (cat-
alog no. sc-2004; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or
rabbit anti-mouse IgG conjugated to horseradish peroxidase (HRP) (1:
10,000) (catalog no. sc-358914; Santa Cruz) with enhanced chemilumi-
nescence (ECL) reagents (Pierce, Rockford, IL).
LF, EF, DTR, and LFN-DTA were expressed in E. coli BL21(DE3) (In-
vitrogen), induced with 1 mM isopropyl--d-1-thiogalactopyranoside
(IPTG) for 4 h, using the Champion pet-SUMO expression system (In-
vitrogen). Cell pellets were lysed by sonication in lysis buffer (20 mM
Tris-HCl [pH 8.0], 150 mM NaCl, 10 mM imidazole, 10 mg lysozyme,
2 mg DNase I, supplemented with a complete Roche protease inhibitor
tablet). Following sonication, the lysates were cleared by centrifugation
and loaded onto a 3-ml bed volume of nickel-nitrilotriacetic acid (Ni-
NTA) agarose (Qiagen, Valencia, CA). The resin was washed with 15
column volumes of wash buffer (20 mM Tris-HCl [pH 8.0], 150 mM
NaCl, 20 mM imidazole) and eluted with the same buffer supplemented
with 250 mM imidazole. The resulting puriﬁed protein was transferred
into 20 mM Tris-HCl (pH 8.0) and 150 mM NaCl, and cleaved with
SUMO protease (Invitrogen) overnight at 4°C. Uncleaved His-SUMO
fusion and SUMO protease were removed by a second round of Ni-NTA
chromatography, in which the ﬂowthrough contained the cleaved prod-
uct of interest.
SDS resistance. Exposure to acidic pH causes the structural transfor-
mation from PA prepores to pores, which is marked by the presence of
SDS-resistant oligomers. WT PA, mPA, mPA-EGF, and mPA-DTR pre-
pores(5g)wereincubatedinpH5.5buffer(100mMKCl,1mMEDTA,
and 10 mM [each] sodium oxalate, potassium phosphate, and morpho-
lineethanesulfonic acid [MES] [pH 5.5]) or pH 8.5 buffer (20 mM Tris
[pH8.5]plus150nMNaCl)for30minatroomtemperature.Eachsample
was then exposed to SDS sample buffer and resolved by SDS-PAGE. Pro-
tein bands were visualized by Coomassie blue staining.
Cellculture.TheCHO-K1celllinewasfromtheAmericanTypeCul-
ture Collection (catalog no. CCL-61) (Manassas, VA). Cells were main-
tainedinHam’sF-12mediumsupplementedwith10%fetalbovineserum
(FBS), 500 U/ml penicillin G, and 500 U/ml streptomycin sulfate (Life
Technologies,Inc.,Carlsbad,CA).TheA431cellline,alsofromtheAmer-
ican Type Culture Collection (catalog no. CCL-1555) was grown in Dul-
becco’s modiﬁed Eagle’s medium, with 10% FBS, 500 U/ml penicillin G,
500 U/ml streptomycin sulfate, and 1 mM sodium pyruvate (American
Type Culture Collection).
Cytotoxicityassays.Proteinsynthesisinhibitionwasusedtomeasure
theabilityofWTPAanditsderivativestodeliverLFN-DTAtothecytosol.
CHO-K1 and A431 cells (3.5  104 per well) were exposed to six 10-fold
serial dilutions of LFN-DTA (starting with 10 nM) in combination with
one of the PA83 variants (10 nM). The cells were incubated either for 4 h
(A431) or overnight (CHO-K1) at 37°C. Toxin-containing medium was
removed, and the cells were incubated for1ha t37°C with leucine-
deﬁcientmediumsupplementedwith1Ciof[3H]leucine/ml(PerkinEl-
mer, Billerica, MA). The plates were washed twice with cold phosphate-
buffered saline (PBS) and protein synthesis was measured by the amount
of [3H]leucine protein, as determined by scintillation counting. Percent
protein synthesis was plotted versus the log concentration of LFN-DTA
where each bar represents the average of three experiments.
Competition experiments were performed as described above but
witha50-foldmolarexcessofsolubleEGF(Prospec,EastBrunswick,NJ)
or 10-fold excess of DTR to compete with mPA-EGF and mPA-DTR,
respectively. Control experiments were also performed with a 10-fold
excess of the PA-binding VWA domain of ANTRX2 (ANTHRX2), which
was produced recombinantly as described previously (16).
MEK cleavage. Translocation of LF to the cytosol of A431 cells was
monitored by Western blotting against cell lysates for mitogen-activated
proteinkinasekinase1(MEK1).A431cells(1106cells)wereexposedto
lethaltoxin(10nMPA83variantand100nMLF)for3hat37°C.Thecells
were harvested in 100 l of Tris-buffered saline (20 mM Tris-HCl,
150 mM NaCl [pH 7.4]), suspended in SDS-PAGE sample buffer, and
immediately incubated at 100°C for 20 min. The lysates were resolved by
SDS-PAGE and transferred to a PVDF membrane (Invitrogen). The
membranes were blocked with Tris-buffered saline (pH 7.4) containing
2% BSA and hybridized with either anti-MEK1 antibodies (1:1,000) (cat-
alogno.Ab32071;Abcam)oranti-glyceraldehyde-3-phosphatedehydro-
genase(anti-GAPDH)antibodies(1:2,500)(catalogno.Ab9485;Abcam).
Primaryantibodiesweredetectedwithgoatanti-rabbitIgGconjugatedto
HRP (1:20,000) (catalog no. sc-2004; Santa Cruz) and ECL reagents
(Pierce).
Edema factor adenylate cyclase assay. A competition enzyme-linked
immunoassay (Cell Signaling Technology, Danvers, MA) was used to de-
termine the amount of cAMP generated in A431 cells upon exposure to
EF.A431cells(3.5104)wereplatedina96-welltissuecultureplateand
incubated with EF (50 nM) in the presence or absence of a PA variant
(10nMWTPA,PAF427H,mPA,ormPA-EGF).After1h,themediumwas
removed and cells were washed twice with 200 l of ice-cold PBS. Adher-
entcellswerelysedwith100lof1celllysisbufferandincubatedonice
for 10 min. Each cell lysis supernatant (50 l) was combined with HRP-
linked cAMP solution (50 l), added to the cAMP assay plate, and incu-
bated at room temperature for 3 h. Each well was then washed four times
with200lof1washbuffer,and3,3=,5,5=-tetramethylbenzidine(TMB)
substrate (100 l) was added to each well for 10 min. Following the addi-
tion of STOP solution (100 l), the absorbance of each well was read at
450 nm and used to estimate the amount of cAMP based on a standard
curve.TheamountofintracellularcAMPproducedbyEFinthepresence
andabsenceofeachPAvariantwasplottedasahistogramwhereeachbar
represents the average of four experiments.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
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Figure S1, TIFF ﬁle, 0.3 MB.
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